Consumer advertising of psychiatric medications biases the public against nonpharmacological treatment

Ethical Human Psychology and Psychiatry

Volumn 7, Issue 3, 2005, Pages 175-179

  Lacasse, Jeffrey R ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

Author keywords

Antidepressant; Consumer advertising; Depression; Psychotherapy; Sertraline

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

DEPRESSION; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOTHERAPY; REVIEW; UNITED STATES;

EID: 27744565104     PISSN: 15594343     EISSN: 19389000     Source Type: Journal    
DOI: 10.1891/1559-4343.7.3.175     Document Type: Review

References (16)

1. Abramson, J. (2004). Overdo$ed America: The broken promise of American medicine. New York: HarperCollins.
2. Angell, M. (2004). The truth about the drug companies: How they deceive us and what to do about it. New York: Random House.
3. Antonuccio, D. O., Danton, W. G., & DeNelsky, G. Y. (1995). Psychotherapy versus medication for depression: Challenging the conventional wisdom. Professional Psychology: Research and Practice, 26, 574-585.
4. Babyak, M., Blumenthal, J. A., Herman, S., Khatri, P., Doraiswamy, M., Moore, K., et al. (2000). Exercise treatment for major depression: Maintenance of therapeutic benefit at 10 months. Psychosomatic Medicine, 62(5), 633-638.
5. Blumenthal, J. A., Babyak, M. A., Moore, K. A., Craighead, W. E., Herman, S., Khatri, P., et al. (1999). Effects of exercise training on older patients with major depression. Archives of Internal Medicine, 159(19), 2349-2356.
6. Breggin, P. R., & Cohen, D. (1999). Your drug may be your problem: How and why to stop taking psychiatric medications. Reading, MA: Perseus Books.
7. Eli Lilly. (2005). Prozac.com treatment information. Retrieved June 12, 2005, from http://www.prozac .com/disease_information/treatment_depression.jsp? reqNavId=1.1.4
8. Food and Drug Administration Division of Drug Marketing, Advertising, and Communications. (2005a). Zoloft warning letter. Retrieved May 9, 2005, from http://www.fda.gov/cder/warn/ 2005/zoloft_letter.pdf
9. Food and Drug Administration Division of Drug Marketing, Advertising, and Communications. (2005b). Crestor warning letter. Retrieved May 9, 2005, from http://www.fda.gov/cder/warn/ 2005/Crestor_letter.pdf
10. Glenmullen, J. (2005). The antidepressant solution: A step-by-step guide to safely overcoming antidepressant withdrawal, dependence, and "addiction." New York: Free Press.
11. Hollon, S. D., DeRubeis, R. J., Shelton, R. C., Amsterdam, J. D., Salomon, R. M., O'Reardon, J. P., et al. (2005). Prevention of relapse following cognitive therapy versus medications in moderate to severe depression. Archives of General Psychiatry, 62(4), 417-422.
12. Lacasse, J. R., & Leo, J. (2005). Serotonin and depression: A disconnect between consumer advertisements and the scientific literature. Unpublished manuscript.
13. Pfizer, Inc. Zoloft prescribing information. Retrieved August 1st, 2005 from http://www.zoloft.com/ pdf/ZoloftUSPI.pdf
14. Pfizer, Inc. (2005a). Lorraine Bracco testimonial. Retrieved May 15, 2005, from www.Depressionhelp .com
15. Pfizer, Inc. (2005b). Zoloft Web site: About Zoloft. Retrieved June 15, 2005, from http://www.zoloft .com/zoloft/zoloft.portal?_nfpb= true&_pageLabel=common_questions
16. United States General Accounting Office. (2002). Prescription drugs: FDA oversight of direct-to-consumer advertising has limitations. Retrieved February 1, 2005, from http://www.gao.gov/ new.items/d03177.pdf